Department of Biomolecular Engineering, Graduate School of Engineering, Nagoya University, Nagoya, Japan.
Department of Infectious Diseases and Immunology, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Sci Adv. 2020 Oct 14;6(42). doi: 10.1126/sciadv.abd3916. Print 2020 Oct.
To combat severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) and any unknown emerging pathogens in the future, the development of a rapid and effective method to generate high-affinity antibodies or antibody-like proteins is of critical importance. We here report high-speed in vitro selection of multiple high-affinity antibody-like proteins against various targets including the SARS-CoV-2 spike protein. The sequences of monobodies against the SARS-CoV-2 spike protein were successfully procured within only 4 days. Furthermore, the obtained monobody efficiently captured SARS-CoV-2 particles from the nasal swab samples of patients and exhibited a high neutralizing activity against SARS-CoV-2 infection (half-maximal inhibitory concentration, 0.5 nanomolar). High-speed in vitro selection of antibody-like proteins is a promising method for rapid development of a detection method for, and of a neutralizing protein against, a virus responsible for an ongoing, and possibly a future, pandemic.
为了应对严重急性呼吸综合征相关冠状病毒 2（SARS-CoV-2）和未来任何未知的新兴病原体，开发一种快速有效的方法来产生高亲和力的抗体或抗体样蛋白至关重要。我们在这里报告了针对包括 SARS-CoV-2 刺突蛋白在内的各种靶标的多种高亲和力抗体样蛋白的高速体外选择。针对 SARS-CoV-2 刺突蛋白的单域抗体序列仅在 4 天内成功获得。此外，获得的单域抗体能够从患者的鼻腔拭子样本中有效捕获 SARS-CoV-2 颗粒，并对 SARS-CoV-2 感染表现出高中和活性（半最大抑制浓度为 0.5 纳摩尔）。抗体样蛋白的高速体外选择是一种很有前途的方法，可用于快速开发针对正在进行的（可能是未来的）大流行病毒的检测方法和中和蛋白。
Zotero 插件
